Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 26, Issue 32, 2008, Pages 5240-5247

  Goodman, Karyn A ^a   Riedel, Elyn ^a   Serrano, Victoria ^a   Gulati, Subhash ^a   Moskowitz, Craig H ^a   Yahalom, Joachim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MITOGUAZONE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHILD; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SECOND CANCER; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEW YORK CITY; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; RECURRENCE; RISK ASSESSMENT; SALVAGE THERAPY; SEER PROGRAM; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE;

EID: 56049120865     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.5507     Document Type: Article

References (43)

1. Mink S, Armitage J: High-dose therapy in lymphomas: A review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist 6:247-256, 2001
2. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822, 1997
3. Hoppe RT, Advani RH, Bierman PJ, et al: Hodgkin disease/lymphoma: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:210-230, 2006
4. Moskowitz CH, Kewalramani T, Nimer SD, et al: Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124:645-652, 2004
5. Adams M, Lipsitz S, Colan S, et al: Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 22:3139-3148, 2004
6. Swerdlow A, Higgins C, Smith P, et al: Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 99:206-214, 2007
7. Dores GM, Coté TR, Travis LB: New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma, in Curtis RE FD, Ron E, Ries LAG, et al (eds): New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD, National Cancer Institute, NIH Publ. No. 05-5302, 2006
8. Ng AK, Bernardo MP, Weller E, et al: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996, 2002
9. Hodgson D, Gilbert E, Dores G, et al: Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25:1489-1497, 2007
10. Lund MB, Kongerud J, Nome O, et al: Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol 6:495-501, 1995
11. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063-1073, 1994
12. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994
13. Ng AK, Bernardo MP, Weller E, et al: Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20:2101-2108, 2002
14. Diehl V, Brillant C, Engert A, et al: HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 23:561s, 2005 (suppl; abstr 6506)
15. Horning S, Hoppe R, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
16. Andrykowski M, Bishop M, Hahn E, et al: Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol 23:599-608, 2005
17. Syrjala K, Langer S, Abrams J, et al: Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 23:6596-6606, 2005
18. Baker F, Zabora J, Polland A, et al: Reintegration after bone marrow transplantation. Cancer Pract 7:190-197, 1999
19. Bush NE, Donaldson GW, Haberman MH, et al: Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: A longitudinal follow-up of 415 patients. Blood Marrow Transplant 6:576-591, 2000
20. Hjermstad MJ, Evensen SA, Kvaloy SO, et al: Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: A prospective study. J Clin Oncol 17:706-718, 1999
21. Neitzert CS, Ritvo P, Dancey J, et al: The psychosocial impact of bone marrow transplantation: A review of the literature. Bone Marrow Transplant 22:409-422, 1998
22. Robison LL, Mertens AC, Boice JD, et al: Study design and cohort characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative project. Med Pediatr Oncol 38:229-239, 2002
23. Bassal M, Mertens A, Taylor L, et al: Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 24:476-483, 2006
24. Moskowitz CH, Nimer SD, Zelenetz AD, et al: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 97:616-623, 2001
25. Yahalom J, Gulati S, Shank B, et al: Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. Int J Radiat Oncol Biol Phys 17:915-922, 1989
26. Yahalom J, Gulati SC, Toia M, et al: Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 11:1062-1070, 1993
27. Aaronson N, Ahmedzai S, Bergman B, et al: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
28. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 457-481, 1958
29. Fine J, Gray RJ: A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
30. Gray R: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
31. SAS User's Guide: Statistics (8.0). 1999
32. Fayers P, Aaronson K, Bjordal D, et al: EORTC QLQ-C30 Scoring Manual (ed 3). Brussels, EORTC Quality of Life Group, 2001, pp 86
33. Schwarz R, Hinz A: Reference data for the quality of life questionnaire EORTC QLQ-C30 in general German population. Eur J Cancer 37:1345-1351, 2001
34. Forrest DL, Hogge DE, Nevill TJ, et al: High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 23:7994-8002, 2005
35. Pedersen-Bjergaard J, Andersen MK, Christiansen DH: Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95:3273-3279, 2000
36. Travis LB, Curtis RE, Stovall M, et al: Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450-1457, 1994
37. Winick NJ, McKenna RW, Shuster JJ, et al: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:209-217, 1993
38. Travis LB, Hill D, Dores GM, et al: Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97:1428-1437, 2005
39. Travis LB, Hill DA, Dores GM, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465-475, 2003
40. van Leeuwen F, Klokman W, Stovall M, et al: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95:971-980, 2003
41. Yahalom J: Breast cancer after Hodgkin disease: Hope for a safer cure. JAMA 290:529-531, 2003
42. Syrjala K, Langer S, Abrams J, et al: Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA 291:2335-2343, 2004
43. Yahalom J: Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol 24:544-548, 2006